TransMedics Group (TMDX) Announces Scheduling of OCS Heart FDA Advisory Committee Meeting

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the FDA's Office of Health Technology 2 (Cardiovascular Devices) has communicated its intent to hold a Circulatory Systems Device Advisory Panel meeting on April 6, 2021 to review TransMedics' premarket approval application for the OCS Heart System.

"We are looking forward to this important milestone and to hopefully achieving a positive conclusion of the FDA's review process of our OCS Heart PMA application," said Waleed Hassanein, M.D., President and Chief Executive Officer.

You May Also Be Interested In

• Novartis DM1 drug trial misses primary endpoint in Phase III study
• Vaxcyte names new CMO, CLO and narrows VAX-31 data timeline
• FDA grants fast track status to Liquidia's Yutrepia for rare condition